Deucravacitinib Improves Patient-Reported Outcomes for Psoriatic Arthritis
Deucravacitinib, a TYK-2 inhibitor, was linked with significant improvements in patient-reported outcomes (PROs) in patients with active psoriatic arthritis (PsA), according to results from a phase 2 trial. To assess the effects of deucravacitinib in this patient population, the study authors conducted a double-blind and randomized trial that included 203 patients with active PsA who were assigned to receive either deucravacitinib at doses of 6 mg or 12 mg once daily or a placebo over a period of 16 weeks. Key secondary endpoints included changes from baseline at Week 16 in the Health Assessment Questionnaire Disability Index (HAQ-DI) and the 36-item Short Form Health Survey (SF-36) physical component summary (PCS) score. Additional PROs (fatigue, pain, and mental health) were also assessed. The results showed that both doses of deucravacitinib led to significant improvements in HAQ-DI and SF-36 PCS scores compared to the placebo group. Moreover, a higher proportion of patients receivi